| Study | Number of patients | Age | Gender (male/female) | Interventions | Control group | Intervention duration (day) | Outcome assessment | Length of follow-up | Region | Intervention group | Control group |
| Yu Tong 2017 | 41 | 40 | | 45/36 | Acupoint application+normal treatment | (1) | 30 | 1, 2 | 6 months | Zhejiang, China | Xue Ming 2018 | 45 | 45 | | 46/44 | Acupoint application+normal treatment | (2) | 30 | 1, 5 | Not mentioned | Shanxi, China | Ma Ying 2018 | 66 | 66 | | 65/67 | Acupoint application+normal treatment | (1) | 365 | 2, 4 | 1 year | Henan, China | Wang Long 2017 | 25 | 25 | | 20/30 | Acupoint application+normal treatment | (2) | 28 | 1 | Not mentioned | Liaoning, China | Gao Xiyue 2017 | 31 | 31 | | 34/28 | Acupoint application+normal treatment | (1) | 30 | 6 | 3 months | Sichuan, Chian | Ye Jianlin 2017 | 90 | 90 | | 96/84 | Acupoint application+normal treatment | (2) | 28 | 1, 2 | Not mentioned | Guangdong, China | Li Limei 2019 | 30 | 30 | | 33/27 | Acupoint application+normal treatment | (1) | 90 | 1 | Not mentioned | Guangdong, China | Li Qiaoxiang 2017 | 60 | 60 | | 58/62 | Acupoint application+normal treatment | (1) | 45 | 1, 2, 3, 4 | Not mentioned | Hunan, China | Tang Jianwen 2015 | 48 | 48 | | 54/42 | Acupoint application+normal treatment | (3), (4) | 30 | 1, 2 | Not mentioned | Jiangsu, China | Zhao Qi 2018 | 42 | 42 | | 52/32 | Acupoint application+normal treatment | (8) | 28 | 1, 2, 3, 4 | Not mentioned | Sichuan, Chian | Zhang Xiaoyan 2014 | 50 | 46 | | 55/41 | Acupoint application+normal treatment | (5), (6) | 30 | | Not mentioned | Hebei, China | Gou Li 2020 | 45 | 45 | | 44/46 | Acupoint application+normal treatment | (1), (7) | 28 | 1, 6 | Not mentioned | Henan, China | Sui Aifeng 2015 | 48 | 48 | | 47/49 | Acupoint application+normal treatment | (3), (4) | 1095 | 1, 2 | Not mentioned | Liaoning, China |
|
|
Notes: (1) montelukast, (2) aminophylline, (3) salmeterol, (4) fluticasone propionate, (5) ketotifen, (6) procaterol, (7) budesonide, (8) salbutamol. 1: total effective rate; 2: lung functions (FVC, FEV1,FEV1/FVC, FEF, and PEF); 3: the peripheral blood eosinophil (EOS) count; 4: peripheral blood IgE content; 5: asthma control test(ACT) score; 6: Leicester cough questionnaire (LCQ).
|